Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies

Plain-language summary

This study explores the genetic basis of nicotine addiction and evaluates a smoking cessation program called "Flexiquit." Adults aged 18-60 who are current daily smokers may take part. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

University of Cyprus

Intervention

Flexiquit Smoking Cessation Intervention

Start date

11/1/2023

Estimated completion

10/31/2025

Countries

Cyprus

Related genes

Locations

• Nicosia, Cyprus

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adults aged 18-60 years old
* Current daily cigarette smoker
* Able to understand study procedures and provide informed consent
* For females, non-pregnant and non-lactating

Exclusion Criteria:

* Presence of significant uncontrolled medical conditions (e.g. cardiovascular disease, respiratory disorders, cancer) that could affect smoking behaviors or study participation
* Presence of major uncontrolled psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe depression)
* Current substance use disorder (except nicotine dependence)
* Taking medications that could significantly interfere with study objectives (e.g. medications for smoking cessation)
* Significant cognitive impairment that precludes ability to complete study procedures